Addiction

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...

Hazelden Betty Ford Foundation and Netsmart Collaborate to Enhance Behavioral Healthcare with Meaningful AI and Integrated CareFabric® Platform

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#ArtificialIntelligence--The Hazelden Betty Ford Foundation, a leader in non-profit addiction and behavioral health treatment for 75 years,...

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP marketATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics,...

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and...

error: Content is protected !!